• Explore /
  • Poster
  • / Tumor-infiltrating CD163-positive macrophages and clinical outcomes to first-line nivolumab therapy in patients with advanced clear cell renal cell carcinoma (ccRCC) enrolled in the HCRN GU16-260 trial.

Tumor-infiltrating CD163-positive macrophages and clinical outcomes to first-line nivolumab therapy in patients with advanced clear cell renal cell carcinoma (ccRCC) enrolled in the HCRN GU16-260 trial.

Abstract Poster

Authors

null

Nourhan El Ahmar

Brigham and Women's Hospital, Boston, MA

Nourhan El Ahmar , Sayed Matar , Opeyemi Jegede , Yasmin Nabil Laimon , Varunika Savla , Aseman Bagheri Sheshdeh , Thomas Denize , Razan Assaad Mohanna , Toni K. Choueiri , Paul J. Catalano , David A. Braun , Naomi B. Haas , Hans J. Hammers , Mehmet Asim Bilen , Mark N. Stein , Jeffrey A. Sosman , Catherine J. Wu , David F. McDermott , Michael B. Atkins , Sabina Signoretti

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session C: Renal Cell Cancer; Adrenal, Penile, and Testicular Cancers

Track

Renal Cell Cancer,Adrenal Cancer,Penile Cancer,Testicular Cancer

Sub Track

Translational Research, Tumor Biology, Biomarkers, and Pathology

Clinical Trial Registration Number

NCT05403541

Citation

J Clin Oncol 42, 2024 (suppl 4; abstr 448)

DOI

10.1200/JCO.2024.42.4_suppl.448

Abstract #

448

Poster Bd #

J9

Abstract Disclosures

Similar Posters

First Author: Nourhan El Ahmar

First Author: Tae-Yong Kim

First Author: Jens Bedke

First Author: Pratik Rane